IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process
Points To ‘Limited Value’ Of Efficacy Data; Urges Renewed Education Efforts
• By David Wallace
Comparative efficacy clinical data is largely surplus to requirements, the IGBA says • Source: Shutterstock 
